

ANDROGEN SIGNALLING IN NORMAL AND MALIGNANT BREAST EPITHELIAL CELLS

A thesis submitted to the University of Adelaide in fulfilment of the
requirements for the degree of Doctor of Philosophy

by

Amelia Alice Peters B.Biotech (Hons)

Dame Roma Mitchell Cancer Research Laboratories,

Discipline of Medicine,

The University of Adelaide and

The Hanson Institute

August 2008

Table of Contents

Summary	i
Declaration.....	iii
Acknowledgements.....	iv
Publications arising from this Thesis	vi
Abbreviations.....	ix

CHAPTER 1 - INTRODUCTION

1.1 – Introduction	2
1.1.1 - Structure of the mammary gland	2
1.1.2 - Breast cancer.....	3
1.1.3 - Risk factors for breast cancer.....	3
1.2 - Estrogen signalling in normal and malignant breast cells	5
1.2.1 - Estrogen synthesis in females.....	5
1.2.2 - Estrogen signalling in normal breast cells.....	6
1.2.3 - Estrogen receptor structure and function in the breast	6
1.2.4 - Estrogen signalling in breast cancer cells	8
1.2.5 - Hormonal therapies for breast cancer	9
1.3 - Androgen signalling in normal and malignant breast cells	11
1.3.1 - Androgen synthesis in females	11
1.3.2 - Androgen levels and breast cancer risk	13
1.3.3 - Androgen receptor structure and signalling.....	14
1.3.4 - Androgen signalling in normal breast cells	16
1.3.5 - Androgen signalling in breast cancer cells	19
1.4 - Interaction between estrogen and androgen signalling.....	22
1.5 - Objectives of this Thesis	24

CHAPTER 2 - MATERIALS AND METHODS

2.1 - Materials	27
2.1.1 - Chemicals, solutions and general reagents	27
2.1.2 - Antibodies.....	31
2.1.3 - Cell lines	32
2.1.4 - Receptor agonists and antagonists	33
2.1.5 - Mice	33
2.1.6 - Oligonucleotide primers	34
2.1.7 - Restriction enzymes.....	34
2.1.8 - Expression vectors	34
2.1.9 - Equipment.....	35
2.1.10 - Software	36

2.2 - Buffers and solutions	36
2.3 - Methods.....	40
2.3.1 - Cell culture.....	40
2.3.1.1 - <i>Cell passaging and seeding</i>	40
2.3.1.2 - <i>Cell freezing</i>	41
2.3.1.3 - <i>Cell thawing</i>	41
2.3.1.4 - <i>Charcoal stripping</i>	41
2.3.1.5 - <i>Mycoplasma detection</i>	42
2.3.2 - Preparation of steroid stocks.....	42
2.3.3 - Preparation of plasmid DNA	42
2.3.4 - Estimation of DNA concentration	43
2.3.5 - Luciferase reporter gene assay.....	43
2.3.6 - Immunoblot.....	44
2.3.6.1 - <i>Preparation of lysates</i>	44
2.3.6.2 - <i>Immunoblotting</i>	44
2.3.7 - Cloning	45
2.3.7.1 - <i>Polymerase chain reaction (PCR)</i>	45
2.3.7.2 - <i>Restriction enzyme digest</i>	45
2.3.7.3 - <i>Agarose gel electrophoresis of DNA</i>	46
2.3.7.4 - <i>Gel purification of PCR products and restriction enzyme digest fragments</i> .	46
2.3.7.5 - <i>Ligation</i>	46
2.3.7.6 - <i>Preparation of DH5α competent cells</i>	47
2.3.7.7 - <i>Transformation</i>	47
2.3.7.8 - <i>DNA sequencing</i>	47
2.3.7.9 - <i>Isopropanol precipitation of sequencing reactions</i>	48
2.3.8 - Generation of expression vectors.....	48
2.3.8.1 - <i>Generation of pCMV-AR-T707-23AQNAA</i>	48
2.3.8.2 - <i>Generation of pCMV-AR-T707-ΔDBD</i>	49
2.3.8.3 - <i>Generation of pCMV-AR-T707-C617Y</i>	49
2.3.8.4 - <i>Generation of pSG5-HA-AR-DBD (amino acids 553-622)</i>	50
2.3.9 - Statistical tests	50

CHAPTER 3 - ANDROGEN SIGNALLING IN NORMAL MOUSE MAMMARY GLANDS

3.1 - Introduction.....	52
3.2 - Methods.....	54
3.2.1 - Mice and treatments.....	54
3.2.2 - Pellet implantation	55
3.2.3 - Blood collection and measurement of serum E2	56
3.2.4 - Dissection of the 4 th inguinal mouse mammary gland.....	56
3.2.5 - Paraffin embedding tissues	56
3.2.6 - Whole mount carmine alum staining	56
3.2.7 - Immunohistochemistry	57
3.2.8 - Statistical tests	58
3.3 - Results	58
3.3.1 - Effect of modulation of androgen signalling on the morphology of the mammary gland.....	58

3.3.2 – Effect of DHT and flutamide treatment on breast epithelial cell proliferation	59
3.3.3 – Effect of DHT and flutamide treatment on apoptosis	60
3.3.4 – Effect of DHT and flutamide treatment on serum E2 levels.....	60
3.3.5 - Flutamide treatment inhibits androgen signalling	61
3.4 - Discussion	62

CHAPTER 4 – AR INHIBITS ER α ACTIVITY

4.1 - Introduction.....	69
4.2 - Methods.....	71
4.2.1 - Luciferase reporter gene assay.....	71
4.2.2 - Immunoblot.....	71
4.3 - Results	72
4.3.1 - Establishment of an assay to measure the transactivation activity of ER α	72
4.3.2 - Inhibition of ER α transactivation activity by AR.....	72
4.3.3 - Inhibition of ER α activity by AR does not require the AR N-C interaction.....	73
4.3.4 - Characterisation of the constitutively active AR variant AR-T707.....	74
4.3.5 - Inhibition of ER α activity by AR-T707	74
4.3.6 - AR-T707 has no effect on expression of luciferase.....	75
4.4 - Discussion	76

CHAPTER 5 - FUNCTIONAL EFFECTS OF AR SIGNALLING IN BREAST CANCER CELLS

5.1 - Introduction.....	82
5.2 - Methods.....	83
5.2.1 - Luciferase reporter gene assay.....	83
5.2.1.1 - Immunoblot with lysates from luciferase reporter gene assay	84
5.2.2 - Preparation of lysates for immunoblot.....	84
5.2.2.1 - Cells treated with steroids	84
5.2.2.2 - Cells transiently transfected with tet-regulated vectors	84
5.2.3 - Generation of a tet-inducible T-47D breast cancer subline	85
5.2.3.1 - Cloning pBI-EGFP-ART707.....	85
5.2.3.2 - Electroporation	85
5.2.3.3 - Selection of clones	86
5.2.3.4 - Testing expression of EGFP and AR-T707 in the stable clones	86
5.2.4 - Cell proliferation assays	87
5.2.4.1 - Treatment of stable cell lines.....	87
5.2.4.2 - Counting viable cells	87
5.2.5 - Adenoviral transduction.....	87
5.2.5.1 - Cloning pAD-ART707.....	87
5.2.5.2 - Amplification of adenovirus.....	88
5.2.5.3 - Preparation of adenovirus stock.....	89
5.2.5.4 - CsCl purification of adenovirus.....	89
5.2.5.5 - Titration of adenoviral stock.....	90
5.2.5.6 - Determining the ratio of infectious particles/total viral particles.....	90

5.2.5.7 - Transduction of T-47D breast cancer cells with adenovirus.....	91
5.2.5.8 - X-Gal stain.....	91
5.2.5.9 - Immunoblot with lysates from the cell proliferation assay.....	91
5.2.5.10 - Immunoblot with lysates from cells transduced with adenovirus.....	92
5.3 - Results	92
5.3.1 - AR inhibits endogenous ER transactivation activity in T-47D breast cancer cells	92
5.3.2 - A comparison of T-47D and T-47D tet-on breast cancer cell lines.....	93
5.3.3 - Doxycycline induces expression of AR-T707 transiently expressed in T-47D tet-on cells	94
5.3.4 - Characterisation of T-47D tet-on clones.....	95
5.3.5 - Optimisation of adenoviral transduction in T-47D breast cancer cells	96
5.3.6 - Adenoviral mediated expression of AR-T707 inhibits the proliferation of T-47D breast cancer cells	97
5.3.7 - Adenoviral mediated expression of AR-T707 inhibits expression of an estrogen regulated gene in T-47D breast cancer cells.....	98
5.3.8 - Adenoviral mediated expression of AR-T707 inhibits E2-induced proliferation of T-47D breast cancer cells	98
5.3.9 - Effects of AR-T707 on E2-induced expression of estrogen regulated genes in T-47D breast cancer cells	99
5.4 - Discussion	99

CHAPTER 6 – MECHANISM OF INHIBITION OF ER α ACTIVITY BY AR

6.1 - Introduction.....	105
6.2 - Methods.....	107
6.2.1 - Co-immunoprecipitation assay (CoIP)	107
6.2.2 - Luciferase reporter gene assay.....	108
6.2.3 - Immunoblot of samples from reporter gene assays	108
6.2.4 - Mobility shift assay.....	108
6.2.4.1 - Preparation of nuclear extracts.....	108
6.2.4.2 - Hybridisation of oligonucleotides.....	109
6.2.4.3 - Labelling oligonucleotides.....	109
6.2.4.4 - Mobility shift assay.....	109
6.2.5 - Molecular modelling and molecular dynamic simulation	110
6.2.6 - Chromatin immunoprecipitation (ChIP).....	111
6.3 - Results	112
6.3.1 - Interaction between ER α and AR.....	112
6.3.2 - The regions of AR required for inhibition of ER α activity by AR	113
6.3.3 - The DBD of AR is required for inhibition of ER α activity by AR	114
6.3.4 - The AR-DBD inhibits ER α activity	116
6.3.5 - AR binds to a consensus estrogen response element.....	116
6.3.6 - AR is recruited to the promoters of endogenous estrogen regulated genes.....	118
6.4 - Discussion	118

CHAPTER 7 - GENERAL DISCUSSION

7.1 - Androgen signalling in breast epithelial cells.....	126
7.2 - Major findings of this thesis.....	126
7.2.1 - Androgen signalling inhibits the growth of normal mammary glands	126
7.2.2 - AR inhibits breast cancer cell proliferation by inhibiting ER α activity	127
7.2.3 - Mechanism by which AR inhibits ER α activity in breast cancer cells	129
7.3 - Future directions.....	132
7.3.1 - Further investigation of the effect of AR in breast cells <i>in vitro</i> and <i>in vivo</i>	132
7.3.2 - Further investigation of the mechanism by which AR inhibits ER α activity.....	133
7.3.3 - Investigation into the role of androgen signalling in human breast cells <i>in vivo</i>	134
7.3.4 - Use of the AR as a therapeutic treatment for breast cancer.....	135
7.4 - Summary and conclusions.....	136
Appendix 1 - Plasmid constructs	138
Bibliography	139

Summary

The growth and survival of normal breast epithelial cells and breast cancer cells is promoted by estrogens. In contrast, androgens inhibit the proliferation of normal and malignant breast epithelial cells. While this effect of androgens on breast cells appears to be androgen receptor (AR) dependent, the precise mechanism of inhibition and its functional significance are unknown. The aims of this thesis were to investigate the effect of androgen signalling on growth of normal and malignant breast epithelial cells, and to assess the interactions between androgen and estrogen signalling in the breast.

To investigate the role of androgen signalling in the growth and development of the normal mammary gland, female mice were treated with either the native androgen 5 α -dihydrotestosterone (DHT) or the antiandrogen, flutamide. Analysis of the mammary glands at the end of the treatment period demonstrated that DHT reduced ductal branching and mammary epithelial cell proliferation when treatment commenced mid-puberty. Conversely, flutamide treatment that commenced post-puberty significantly increased ductal branching and proliferation of mammary epithelial cells. This data demonstrates that androgen signalling inhibits proliferation in the normal mammary gland, and may therefore oppose to the growth stimulatory effects of estrogen signalling to regulate breast growth and development.

The antiproliferative effects of androgens on breast epithelial cells may be due in part to direct AR-mediated activation of androgen regulated genes, or alternatively, androgens could act indirectly through AR to inhibit estrogen receptor alpha (ER α) activity. Expression of full-length AR or a truncated, constitutively active AR (AR-T707) significantly inhibited the activity of ectopically expressed ER α in MDA-MB-231 breast cancer cells (ER α - and AR-negative), in a dose-dependent manner. The functional consequences of inhibition of estrogen signalling by overexpressing AR were investigated in the T-47D breast cancer cell line (ER α - and AR-positive). Expression of AR-T707 in T-47D cells resulted in inhibition of both basal

and estradiol-induced cell proliferation and a marked reduction in the steady-state protein levels of the estrogen regulated gene, PR.

The final chapter investigated the mechanism by which AR inhibits ER α activity. A co-immunoprecipitation assay demonstrated an interaction between ectopically expressed AR and ER α in COS-1 cells, but not endogenous AR and ER α in a breast cancer cell line. To delineate the regions of AR required for inhibition of ER α signalling, various functional domains of the AR were mutated or deleted. Reporter gene assays showed that the inhibitory effects of AR were abrogated by deletion or mutation of the DNA binding domain (DBD). Furthermore, overexpression of the AR-DBD alone was sufficient to inhibit ER α activity. Consistent with a requirement for the DBD of AR to inhibit ER α activity, mobility shift assays demonstrated binding of AR to the *Xenopus* vitellogenin A2 consensus estrogen response element (cERE); however AR/ER α heterodimers were not detected on a cERE. Consistent with these findings, molecular modelling demonstrated that it is feasible for the DBD of AR to bind to a cERE and that it is unlikely that AR/ER α heterodimers could bind. Chromatin immunoprecipitation demonstrated recruitment of AR to the promoters of endogenous estrogen regulated genes. The findings suggest that the inhibitory effect of AR on ER α activity may occur either via formation of non-functional AR/ER α heterodimers that are unable to bind to EREs, or AR homodimers competing effectively for binding to EREs, in ER α target genes.

The results in this thesis demonstrate an inhibitory effect of androgen signalling on growth of normal and malignant breast epithelial cells. Additionally, the inhibition of breast epithelial cell proliferation by androgen signalling can be attributed, at least in part, to inhibition of ER α activity. These studies have provided insight into androgen action in the breast, and support a model whereby androgens balance the stimulatory effects of estrogen signalling in normal and malignant breast epithelial cells.

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institute and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give my consent to this copy of my thesis, when deposited in the University library, being made available for loan and photocopy.

Amelia A. Peters

August, 2008

Acknowledgements

This thesis would not have been possible without the support and guidance of numerous people. Firstly and most importantly I would sincerely like to thank my supervisors Dr Lisa Butler and Prof Wayne Tilley who gave me the opportunity to study at the Dame Roma Mitchell Cancer Research Laboratories, and provided financial support for me to attend conferences and visit laboratories abroad. I really appreciate their guidance and encouragement for last 5 years. I am exceptionally grateful to Tina Bianco-Miotto for her valuable support and advice. I would also like to extend my gratitude to Dr Grant Buchanan and Dr Stephen Birrell for their ideas and enthusiasm for the project.

I would like to thank everyone at the Dame Roma Mitchell Cancer Research Laboratories including Jo Treloar, Laura Almeroth, Karen Chiam, Maggie Yard, Marie Pickering, Michelle Newman, Miriam Butler, Ping Lee, Sarah Carter and Theresa Hickey who provided assistance and importantly cake. I would particularly like to acknowledge the members of my laboratory whose work contributed to aspects of this thesis including Melissa O'Loughlin, Jeff Barrett, Elle Need, Elisa Cops and Shalini Jindal. I am also grateful for assistance of Ali Ochnik and Sook Ching Lee with the mice studies and immunohistochemistry. Special thanks to Maggie Centenera for her technical assistance, for performing the mobility shift assays and for reading my thesis. I also wish to thank the PhD girls Deb Marracco, Elle Need and Maggie Centenera for helpful advice and great chats.

I am grateful to the Laboratory Animal Services (University of Adelaide, SA, Australia), Adelaide Microscopy (University of Adelaide, SA, Australia), Wendy Ingham (University of Adelaide, SA, Australia) and Carmela Ricciardelli (University of Adelaide, SA, Australia) for assistance with the mouse mammary gland study in this thesis. Additionally, I wish to thank Carmela Ricciardelli for her assistance with immunohistochemistry and statistical analysis. Peter O'Loughlin (IMVS, Adelaide, SA, Australia) and his laboratory staff provided valuable assistance with the radioimmunoassay.

Thank you to the collaborators of our research group whose work directly contributed to this thesis. Dr Jonathan Harris (Queensland University of Technology, Queensland, Australia) who performed molecular modelling and Dr Li Jia (Norris Comprehensive Cancer Centre, University of Southern California, CA, USA) who performed chromatin immunoprecipitation assays. I wish to thank those who kindly provided material used in the project. Expression vectors were provided by Dr Robert Matusik (The Vanderbilt Prostate Cancer Centre, TN, USA), Prof Alessandro Weisz (Seconda Universita di Napoli, Italy), Prof Pierre Chambon (Collage de France, Illkirch, France), Prof Michael Stallcup (University of Southern California, CA, USA) and Prof Pamela Russell (Prince of Wales Hospital, Randwick, NSW, Australia). The progesterone receptor antibody was provided by Dr Christine Clark (University of Sydney, Westmead Hospital, NSW, Australia).

On a personal note, many thanks must go to my family and friends. I would like to thank Cindy, Tim, Renny and Jon for surfing trips and BBQs. Thank you also to Beka for your interest in my studies and for being a great friend. My housemates for the past year, Renny and Rachel, deserve special mention for being understanding and letting me take over our dining room to write my thesis. Renny, thanks for running with me and Rach, thanks for your delicious curries (even though they were too hot). Thank you to my grandmothers, nanna Pillar and nanna Peters, for thinking that I am very clever. I am especially grateful to my sisters Tiffany and Michelle for listening to me and for not only being the best sisters, but being great friends. Very special thanks must also go to mum and dad, Heather and Michael, for their continuous support. I really appreciate everything you do for me and especially for ensuring that I am always well fed. Lastly, I would like to thank my heavenly Father.

Articles published in scientific journals:

Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate, Buchanan G, Birrell SN, **Peters AA**, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM and Tilley WD *Cancer Research* (2005) 65: 8487-8496

Articles in preparation:

The androgen receptor inhibits estrogen receptor alpha signaling in breast cancer cells by binding to estrogen response elements, **Peters AA**, Bianco-Miotto T, Murphy N, Ricciardelli C, Centenera MM, Buchanan G, Segara D, Henshall SM, Birrell SN, Jia L, Harris JM, Sutherland RL, Butler LM and Tilley WD

Androgen signaling inhibits the proliferation of the mouse mammary gland, **Peters AA**, Bianco-Miotto T, Butler LM and Tilley WD

Abstracts published in the proceedings of scientific meetings:

Androgen receptor status predicts outcome in estrogen receptor positive breast cancers, Tilley WD, Ricciardelli C, Bianco-Miotto T, **Peters AA**, Centenera MM, Segara D, McNeil CM, Henshall SM, Sutherland RL, Sakko AJ, Buchanan G, Birrell SN and Butler LM, The Endocrine Society's 90th annual meeting, San Francisco, California, USA, June 2008

The androgen receptor inhibits estrogen receptor alpha (ER) signaling and predicts outcome in ER positive breast cancers, Tilley WD, Ricciardelli C, Bianco-Miotto T, **Peters AA**, Centenera MM, Moore NL, Murphy N, Segara D, McNeil C, Henshall SM, Sutherland RL, Sakko AJ, Buchanan G, Birrell SN and Butler LM, Era of Hope 2008 Meeting, Baltimore, MD, USA, June 2008

The androgen receptor attenuates estrogen signaling in breast cancer cells, **Peters AA**, Bianco-Miotto T, Murphy N, Ricciardelli C, Centenera MM, Buchanan G, Segara D, Henshall SM, Birrell SN, Sutherland RL, Butler LM and Tilley WD, Gordon Mammary Gland Biology Conference, Newport, RI, USA, June 2007

The protective role of AR in breast cancer cells is in part due to its ability to inhibit ER α signaling, **Peters AA**, Bianco-Miotto T, Murphy N, Ricciardelli C, Centenera MM, Buchanan G, Segara D, Henshall SM, Birrell SN, Butler LM, Sutherland RL and Tilley WD, The Endocrine Society's 89th annual meeting, Toronto, Ontario, Canada, June 2007

Inhibition of estrogen receptor alpha activity in breast cancer cells by the androgen receptor, **Peters AA**, Bianco-Miotto T, Moore NL, Centenera MM, Buchanan G, Birrell SN, Butler LM and Tilley WD, The 98th annual meeting for the American Association for Cancer Research, Anaheim, CA, USA, April 2007

Inhibition of estrogen receptor alpha activity in breast cancer cells by the androgen receptor, **Peters AA**, Bianco-Miotto T, Centenera MM, O'Loughlin M, Buchanan G, Butler LM and Tilley WD, 3rd PacRim Breast and Prostate Cancer Meeting, Fraser Island, Queensland, Australia, November 2006

Inhibition of estrogen signalling in breast cancer cells by the androgen receptor, **Peters AA**, Buchanan G, Bianco-Miotto T, Butler LM and Tilley WD, National meeting for the Australian Society for Medical Research, Couran Cove, Queensland, Australia, November 2005

Inhibition of estrogen signalling in breast cancer cells by the androgen receptor, **Peters AA**, Buchanan G, Bianco-Miotto T, Butler LM, Tilley WD, Annual meeting for the Australian Society for Medical Research, Adelaide, SA, Australia, June 2005

Inhibition of estrogen signalling in breast cancer cells by the androgen receptor, **Peters AA**,
Buchanan G, Butler LM, Tilley WD, Annual meeting for the Australian Society for Medical
Research, Adelaide, SA, Australia, June 2004

Abbreviations

17 β -HSD	17 β -hydroxysteroid dehydrogenase
3 α -HSD	3 α -hydroxysteroid dehydrogenase
3 β -HSD	3 β -hydroxysteroid dehydrogenase
A	adenine
Ab	antibody
Ad-ART707	adenovirus expressing AR-T707
Ad-LacZ	adenovirus expressing LacZ
AF	activation function
AI	aromatase inhibitor
ALU	arbitrary light units
APS	ammonium persulphate
AR	androgen receptor
ARA 70	androgen receptor coactivator 70
ARE	androgen response element
AR-T707	AR construct truncated at amino acid 707
ATAC	Arimidex, Tamoxifen Alone or in Combination trial
<i>BRCA1</i>	breast cancer susceptibility gene 1
<i>BRCA2</i>	breast cancer susceptibility gene 2
BrdU	5-bromo-2' deoxyuridine
BSA	bovine serum albumin
C	cytosine
cARE	consensus androgen response element
cDNA	complementary DNA
cERE	consensus estrogen response element
ChIP	chromatin immunoprecipitation
cHRT	combined estradiol and progestin hormonal replacement therapy
CoIP	co-immunoprecipitation
COUP-TF	orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor
CPE	cytopathic effect
CTSD	cathepsin D gene
DAB	3,3'-Diaminobenzidine
DBD	DNA binding domain
DCC	dextran coated charcoal
DHEA	dehydroepiandrosterone

DHEA-S	dehydroepiandrosterone sulphate
DHT	5 α -dihydrotestosterone
DMEM	Dulbecco's modified eagle medium
DMSO	dimethyl sulphoxide
DNA	deoxyribonucleic acid
dNTPs	deoxyribonucleotide triphosphates
dox	doxycycline
DTT	dithiothreitol
E2	17 β -estradiol
ECL	enhanced chemiluminescence
EDTA	ethylenediamine tetra-acetic acid
EGFP	enhanced green fluorescent protein
ER	estrogen receptor alpha and estrogen receptor beta
ER α	estrogen receptor alpha
ERE	estrogen response element
ER β	estrogen receptor beta
FBS	fetal bovine serum
FSH	follicle-stimulating hormone
G	guanine
GR	glucocorticoid receptor
GU	genitourinary
H	hinge region
HRP	horseradish peroxidase
HRT	hormone replacement therapy
Hsp	heat shock protein
IgG	immunoglobulin
IMPACT	IMmediate Preoperative Anastrozole, Tamoxifen or Combined with Tamoxifen
KO	knockout
LB	luria broth
LBD	ligand binding domain
LH	luteinising hormone
Luc	luciferase
MMTV	mouse-mammary tumour virus
MOIs	multiplicity of infections
MPA	medroxyprogesterone acetate
MR	mineralocorticoid receptor
n	any nucleotide

NTD	amino-terminal transactivation domain
OD	optical density
PAGE	polyacrylamide gel electrophoresis
PBS	phosphate buffered saline
PCR	polymerase chain reaction
PGR	progesterone receptor gene
PMSF	phenylmethanesulphonyl fluoride
PR	progesterone receptor
PRF	phenol red free
PROACT	Preoperative Arimidex Compared with Tamoxifen
PSA	prostate-specific antigen
RAR	retinoic acid receptor
RNA	ribonucleic acid
RPMI	Roswell Park Memorial Institute
rtTA	reverse tetracycline controlled transactivator
RXR	retinoid X receptor
SD	standard deviation
SDS	sodium dodecyl sulfate
SEM	standard error of the mean
SERM	selective estrogen receptor modulator
SHBG	sex hormone-binding globulin
T	thymine
TAE	tris acetate EDTA
Tam	tamoxifen
TBE	tris borate EDTA
TBS	tris buffered saline
TBST	tris buffered saline tween 20
TE	tris-EDTA
TEMED	N,N,N',N'-tetramethylethylenediamine
tk	thymidine kinase
TR α	thyroid hormone receptor alpha
TR4	testicular orphan receptor 4
TRE	tetracycline response element
UV	ultra violet light
WHI	Women's Health Initiative
wt	wild-type
x	any amino acid

X-gal	5-bromo-4-chloro-3-indolyl -D-galactopyranoside
Δ	deletion

Units:

bp	base pairs
cpm	counts per minute
Ci	curie(s)
°C	degrees Celsius
Da	Dalton(s)
g	gram(s)
g	relative centrifugal force
kDa	kilo Dalton
kb	kilobases
L	litre
min	minute(s)
M	molar (moles per litre)
mA	milliampere
rpm	revolutions per minute
sec	seconds(s)
U	units
V	volts